Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement
Solubility development of supramolecular host–guest interaction between Alverine citrate with α and β-cyclodextrins were studied throughout the article. 2:1 host to guest stoichiometry of the inclusion complexation in the solution phase were confirmed by the Job’s plot. The IR, DSC, SEM and PXRD dat...
Ausführliche Beschreibung
Autor*in: |
Rajbanshi, Biplab [verfasserIn] Das, Koyeli [verfasserIn] Roy, Debadrita [verfasserIn] Saha, Subhadeep [verfasserIn] Roy, Mahendra Nath [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2022 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
Enthalten in: Journal of molecular liquids - New York, NY [u.a.] : Elsevier, 1983, 370 |
---|---|
Übergeordnetes Werk: |
volume:370 |
DOI / URN: |
10.1016/j.molliq.2022.121036 |
---|
Katalog-ID: |
ELV009033114 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | ELV009033114 | ||
003 | DE-627 | ||
005 | 20230524151321.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230510s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.molliq.2022.121036 |2 doi | |
035 | |a (DE-627)ELV009033114 | ||
035 | |a (ELSEVIER)S0167-7322(22)02575-2 | ||
040 | |a DE-627 |b ger |c DE-627 |e rda | ||
041 | |a eng | ||
082 | 0 | 4 | |a 540 |q DE-600 |
084 | |a 35.21 |2 bkl | ||
100 | 1 | |a Rajbanshi, Biplab |e verfasserin |4 aut | |
245 | 1 | 0 | |a Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement |
264 | 1 | |c 2022 | |
336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Solubility development of supramolecular host–guest interaction between Alverine citrate with α and β-cyclodextrins were studied throughout the article. 2:1 host to guest stoichiometry of the inclusion complexation in the solution phase were confirmed by the Job’s plot. The IR, DSC, SEM and PXRD data turn out to be supportive about the phenomenon, inclusion complexation. Association constants and thermodynamic parameters of the inclusion complexes were obtained using UV–vis and spectrofluorometric measurement. The mechanism of inclusion complexation was explored by 1H and 2D ROESY NMR spectroscopy. Binding ability of the drug molecule, Alverine citrate with the HSA and the controlled release of the drug molecule from inclusion complexes were studied at PH-7.4 by spectrofluorimetricaly. Studied phenomenon thus develops the solubility of merely soluble drug into water, consequently makes bioavailable and enriches the drug delivery system. | ||
650 | 4 | |a Alverine citrate | |
650 | 4 | |a Cyclodextrin, Human serum albumin | |
650 | 4 | |a Controlled Drug delivery | |
650 | 4 | |a Inclusion Complex | |
650 | 4 | |a Solubility enhancement | |
700 | 1 | |a Das, Koyeli |e verfasserin |4 aut | |
700 | 1 | |a Roy, Debadrita |e verfasserin |4 aut | |
700 | 1 | |a Saha, Subhadeep |e verfasserin |4 aut | |
700 | 1 | |a Roy, Mahendra Nath |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of molecular liquids |d New York, NY [u.a.] : Elsevier, 1983 |g 370 |h Online-Ressource |w (DE-627)302469664 |w (DE-600)1491496-7 |w (DE-576)259483915 |x 1873-3166 |7 nnns |
773 | 1 | 8 | |g volume:370 |
912 | |a GBV_USEFLAG_U | ||
912 | |a SYSFLAG_U | ||
912 | |a GBV_ELV | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_32 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_90 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_101 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_150 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_374 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2004 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2027 | ||
912 | |a GBV_ILN_2034 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2049 | ||
912 | |a GBV_ILN_2050 | ||
912 | |a GBV_ILN_2056 | ||
912 | |a GBV_ILN_2059 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2064 | ||
912 | |a GBV_ILN_2065 | ||
912 | |a GBV_ILN_2068 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2112 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2118 | ||
912 | |a GBV_ILN_2122 | ||
912 | |a GBV_ILN_2129 | ||
912 | |a GBV_ILN_2143 | ||
912 | |a GBV_ILN_2147 | ||
912 | |a GBV_ILN_2148 | ||
912 | |a GBV_ILN_2152 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_2336 | ||
912 | |a GBV_ILN_2507 | ||
912 | |a GBV_ILN_2522 | ||
912 | |a GBV_ILN_2807 | ||
912 | |a GBV_ILN_4035 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4242 | ||
912 | |a GBV_ILN_4251 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4326 | ||
912 | |a GBV_ILN_4333 | ||
912 | |a GBV_ILN_4334 | ||
912 | |a GBV_ILN_4335 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4393 | ||
936 | b | k | |a 35.21 |j Lösungen |j Flüssigkeiten |x Physikalische Chemie |
951 | |a AR | ||
952 | |d 370 |
author_variant |
b r br k d kd d r dr s s ss m n r mn mnr |
---|---|
matchkey_str |
article:18733166:2022----::xlrn2icuinopeeoccoetisnatsamdcavrnctaeoehnigiaal |
hierarchy_sort_str |
2022 |
bklnumber |
35.21 |
publishDate |
2022 |
allfields |
10.1016/j.molliq.2022.121036 doi (DE-627)ELV009033114 (ELSEVIER)S0167-7322(22)02575-2 DE-627 ger DE-627 rda eng 540 DE-600 35.21 bkl Rajbanshi, Biplab verfasserin aut Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement 2022 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Solubility development of supramolecular host–guest interaction between Alverine citrate with α and β-cyclodextrins were studied throughout the article. 2:1 host to guest stoichiometry of the inclusion complexation in the solution phase were confirmed by the Job’s plot. The IR, DSC, SEM and PXRD data turn out to be supportive about the phenomenon, inclusion complexation. Association constants and thermodynamic parameters of the inclusion complexes were obtained using UV–vis and spectrofluorometric measurement. The mechanism of inclusion complexation was explored by 1H and 2D ROESY NMR spectroscopy. Binding ability of the drug molecule, Alverine citrate with the HSA and the controlled release of the drug molecule from inclusion complexes were studied at PH-7.4 by spectrofluorimetricaly. Studied phenomenon thus develops the solubility of merely soluble drug into water, consequently makes bioavailable and enriches the drug delivery system. Alverine citrate Cyclodextrin, Human serum albumin Controlled Drug delivery Inclusion Complex Solubility enhancement Das, Koyeli verfasserin aut Roy, Debadrita verfasserin aut Saha, Subhadeep verfasserin aut Roy, Mahendra Nath verfasserin aut Enthalten in Journal of molecular liquids New York, NY [u.a.] : Elsevier, 1983 370 Online-Ressource (DE-627)302469664 (DE-600)1491496-7 (DE-576)259483915 1873-3166 nnns volume:370 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_374 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2807 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 35.21 Lösungen Flüssigkeiten Physikalische Chemie AR 370 |
spelling |
10.1016/j.molliq.2022.121036 doi (DE-627)ELV009033114 (ELSEVIER)S0167-7322(22)02575-2 DE-627 ger DE-627 rda eng 540 DE-600 35.21 bkl Rajbanshi, Biplab verfasserin aut Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement 2022 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Solubility development of supramolecular host–guest interaction between Alverine citrate with α and β-cyclodextrins were studied throughout the article. 2:1 host to guest stoichiometry of the inclusion complexation in the solution phase were confirmed by the Job’s plot. The IR, DSC, SEM and PXRD data turn out to be supportive about the phenomenon, inclusion complexation. Association constants and thermodynamic parameters of the inclusion complexes were obtained using UV–vis and spectrofluorometric measurement. The mechanism of inclusion complexation was explored by 1H and 2D ROESY NMR spectroscopy. Binding ability of the drug molecule, Alverine citrate with the HSA and the controlled release of the drug molecule from inclusion complexes were studied at PH-7.4 by spectrofluorimetricaly. Studied phenomenon thus develops the solubility of merely soluble drug into water, consequently makes bioavailable and enriches the drug delivery system. Alverine citrate Cyclodextrin, Human serum albumin Controlled Drug delivery Inclusion Complex Solubility enhancement Das, Koyeli verfasserin aut Roy, Debadrita verfasserin aut Saha, Subhadeep verfasserin aut Roy, Mahendra Nath verfasserin aut Enthalten in Journal of molecular liquids New York, NY [u.a.] : Elsevier, 1983 370 Online-Ressource (DE-627)302469664 (DE-600)1491496-7 (DE-576)259483915 1873-3166 nnns volume:370 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_374 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2807 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 35.21 Lösungen Flüssigkeiten Physikalische Chemie AR 370 |
allfields_unstemmed |
10.1016/j.molliq.2022.121036 doi (DE-627)ELV009033114 (ELSEVIER)S0167-7322(22)02575-2 DE-627 ger DE-627 rda eng 540 DE-600 35.21 bkl Rajbanshi, Biplab verfasserin aut Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement 2022 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Solubility development of supramolecular host–guest interaction between Alverine citrate with α and β-cyclodextrins were studied throughout the article. 2:1 host to guest stoichiometry of the inclusion complexation in the solution phase were confirmed by the Job’s plot. The IR, DSC, SEM and PXRD data turn out to be supportive about the phenomenon, inclusion complexation. Association constants and thermodynamic parameters of the inclusion complexes were obtained using UV–vis and spectrofluorometric measurement. The mechanism of inclusion complexation was explored by 1H and 2D ROESY NMR spectroscopy. Binding ability of the drug molecule, Alverine citrate with the HSA and the controlled release of the drug molecule from inclusion complexes were studied at PH-7.4 by spectrofluorimetricaly. Studied phenomenon thus develops the solubility of merely soluble drug into water, consequently makes bioavailable and enriches the drug delivery system. Alverine citrate Cyclodextrin, Human serum albumin Controlled Drug delivery Inclusion Complex Solubility enhancement Das, Koyeli verfasserin aut Roy, Debadrita verfasserin aut Saha, Subhadeep verfasserin aut Roy, Mahendra Nath verfasserin aut Enthalten in Journal of molecular liquids New York, NY [u.a.] : Elsevier, 1983 370 Online-Ressource (DE-627)302469664 (DE-600)1491496-7 (DE-576)259483915 1873-3166 nnns volume:370 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_374 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2807 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 35.21 Lösungen Flüssigkeiten Physikalische Chemie AR 370 |
allfieldsGer |
10.1016/j.molliq.2022.121036 doi (DE-627)ELV009033114 (ELSEVIER)S0167-7322(22)02575-2 DE-627 ger DE-627 rda eng 540 DE-600 35.21 bkl Rajbanshi, Biplab verfasserin aut Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement 2022 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Solubility development of supramolecular host–guest interaction between Alverine citrate with α and β-cyclodextrins were studied throughout the article. 2:1 host to guest stoichiometry of the inclusion complexation in the solution phase were confirmed by the Job’s plot. The IR, DSC, SEM and PXRD data turn out to be supportive about the phenomenon, inclusion complexation. Association constants and thermodynamic parameters of the inclusion complexes were obtained using UV–vis and spectrofluorometric measurement. The mechanism of inclusion complexation was explored by 1H and 2D ROESY NMR spectroscopy. Binding ability of the drug molecule, Alverine citrate with the HSA and the controlled release of the drug molecule from inclusion complexes were studied at PH-7.4 by spectrofluorimetricaly. Studied phenomenon thus develops the solubility of merely soluble drug into water, consequently makes bioavailable and enriches the drug delivery system. Alverine citrate Cyclodextrin, Human serum albumin Controlled Drug delivery Inclusion Complex Solubility enhancement Das, Koyeli verfasserin aut Roy, Debadrita verfasserin aut Saha, Subhadeep verfasserin aut Roy, Mahendra Nath verfasserin aut Enthalten in Journal of molecular liquids New York, NY [u.a.] : Elsevier, 1983 370 Online-Ressource (DE-627)302469664 (DE-600)1491496-7 (DE-576)259483915 1873-3166 nnns volume:370 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_374 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2807 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 35.21 Lösungen Flüssigkeiten Physikalische Chemie AR 370 |
allfieldsSound |
10.1016/j.molliq.2022.121036 doi (DE-627)ELV009033114 (ELSEVIER)S0167-7322(22)02575-2 DE-627 ger DE-627 rda eng 540 DE-600 35.21 bkl Rajbanshi, Biplab verfasserin aut Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement 2022 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Solubility development of supramolecular host–guest interaction between Alverine citrate with α and β-cyclodextrins were studied throughout the article. 2:1 host to guest stoichiometry of the inclusion complexation in the solution phase were confirmed by the Job’s plot. The IR, DSC, SEM and PXRD data turn out to be supportive about the phenomenon, inclusion complexation. Association constants and thermodynamic parameters of the inclusion complexes were obtained using UV–vis and spectrofluorometric measurement. The mechanism of inclusion complexation was explored by 1H and 2D ROESY NMR spectroscopy. Binding ability of the drug molecule, Alverine citrate with the HSA and the controlled release of the drug molecule from inclusion complexes were studied at PH-7.4 by spectrofluorimetricaly. Studied phenomenon thus develops the solubility of merely soluble drug into water, consequently makes bioavailable and enriches the drug delivery system. Alverine citrate Cyclodextrin, Human serum albumin Controlled Drug delivery Inclusion Complex Solubility enhancement Das, Koyeli verfasserin aut Roy, Debadrita verfasserin aut Saha, Subhadeep verfasserin aut Roy, Mahendra Nath verfasserin aut Enthalten in Journal of molecular liquids New York, NY [u.a.] : Elsevier, 1983 370 Online-Ressource (DE-627)302469664 (DE-600)1491496-7 (DE-576)259483915 1873-3166 nnns volume:370 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_374 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2807 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 35.21 Lösungen Flüssigkeiten Physikalische Chemie AR 370 |
language |
English |
source |
Enthalten in Journal of molecular liquids 370 volume:370 |
sourceStr |
Enthalten in Journal of molecular liquids 370 volume:370 |
format_phy_str_mv |
Article |
bklname |
Lösungen Flüssigkeiten |
institution |
findex.gbv.de |
topic_facet |
Alverine citrate Cyclodextrin, Human serum albumin Controlled Drug delivery Inclusion Complex Solubility enhancement |
dewey-raw |
540 |
isfreeaccess_bool |
false |
container_title |
Journal of molecular liquids |
authorswithroles_txt_mv |
Rajbanshi, Biplab @@aut@@ Das, Koyeli @@aut@@ Roy, Debadrita @@aut@@ Saha, Subhadeep @@aut@@ Roy, Mahendra Nath @@aut@@ |
publishDateDaySort_date |
2022-01-01T00:00:00Z |
hierarchy_top_id |
302469664 |
dewey-sort |
3540 |
id |
ELV009033114 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV009033114</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230524151321.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230510s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.molliq.2022.121036</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV009033114</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-7322(22)02575-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.21</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Rajbanshi, Biplab</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Solubility development of supramolecular host–guest interaction between Alverine citrate with α and β-cyclodextrins were studied throughout the article. 2:1 host to guest stoichiometry of the inclusion complexation in the solution phase were confirmed by the Job’s plot. The IR, DSC, SEM and PXRD data turn out to be supportive about the phenomenon, inclusion complexation. Association constants and thermodynamic parameters of the inclusion complexes were obtained using UV–vis and spectrofluorometric measurement. The mechanism of inclusion complexation was explored by 1H and 2D ROESY NMR spectroscopy. Binding ability of the drug molecule, Alverine citrate with the HSA and the controlled release of the drug molecule from inclusion complexes were studied at PH-7.4 by spectrofluorimetricaly. Studied phenomenon thus develops the solubility of merely soluble drug into water, consequently makes bioavailable and enriches the drug delivery system.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Alverine citrate</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cyclodextrin, Human serum albumin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Controlled Drug delivery</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Inclusion Complex</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Solubility enhancement</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Das, Koyeli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roy, Debadrita</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Saha, Subhadeep</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roy, Mahendra Nath</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of molecular liquids</subfield><subfield code="d">New York, NY [u.a.] : Elsevier, 1983</subfield><subfield code="g">370</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)302469664</subfield><subfield code="w">(DE-600)1491496-7</subfield><subfield code="w">(DE-576)259483915</subfield><subfield code="x">1873-3166</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_374</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2807</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.21</subfield><subfield code="j">Lösungen</subfield><subfield code="j">Flüssigkeiten</subfield><subfield code="x">Physikalische Chemie</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">370</subfield></datafield></record></collection>
|
author |
Rajbanshi, Biplab |
spellingShingle |
Rajbanshi, Biplab ddc 540 bkl 35.21 misc Alverine citrate misc Cyclodextrin, Human serum albumin misc Controlled Drug delivery misc Inclusion Complex misc Solubility enhancement Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement |
authorStr |
Rajbanshi, Biplab |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)302469664 |
format |
electronic Article |
dewey-ones |
540 - Chemistry & allied sciences |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut |
collection |
elsevier |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
1873-3166 |
topic_title |
540 DE-600 35.21 bkl Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement Alverine citrate Cyclodextrin, Human serum albumin Controlled Drug delivery Inclusion Complex Solubility enhancement |
topic |
ddc 540 bkl 35.21 misc Alverine citrate misc Cyclodextrin, Human serum albumin misc Controlled Drug delivery misc Inclusion Complex misc Solubility enhancement |
topic_unstemmed |
ddc 540 bkl 35.21 misc Alverine citrate misc Cyclodextrin, Human serum albumin misc Controlled Drug delivery misc Inclusion Complex misc Solubility enhancement |
topic_browse |
ddc 540 bkl 35.21 misc Alverine citrate misc Cyclodextrin, Human serum albumin misc Controlled Drug delivery misc Inclusion Complex misc Solubility enhancement |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Journal of molecular liquids |
hierarchy_parent_id |
302469664 |
dewey-tens |
540 - Chemistry |
hierarchy_top_title |
Journal of molecular liquids |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)302469664 (DE-600)1491496-7 (DE-576)259483915 |
title |
Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement |
ctrlnum |
(DE-627)ELV009033114 (ELSEVIER)S0167-7322(22)02575-2 |
title_full |
Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement |
author_sort |
Rajbanshi, Biplab |
journal |
Journal of molecular liquids |
journalStr |
Journal of molecular liquids |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
500 - Science |
recordtype |
marc |
publishDateSort |
2022 |
contenttype_str_mv |
zzz |
author_browse |
Rajbanshi, Biplab Das, Koyeli Roy, Debadrita Saha, Subhadeep Roy, Mahendra Nath |
container_volume |
370 |
class |
540 DE-600 35.21 bkl |
format_se |
Elektronische Aufsätze |
author-letter |
Rajbanshi, Biplab |
doi_str_mv |
10.1016/j.molliq.2022.121036 |
dewey-full |
540 |
author2-role |
verfasserin |
title_sort |
exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, alverine citrate for enhancing bioavailability and sustained dischargement |
title_auth |
Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement |
abstract |
Solubility development of supramolecular host–guest interaction between Alverine citrate with α and β-cyclodextrins were studied throughout the article. 2:1 host to guest stoichiometry of the inclusion complexation in the solution phase were confirmed by the Job’s plot. The IR, DSC, SEM and PXRD data turn out to be supportive about the phenomenon, inclusion complexation. Association constants and thermodynamic parameters of the inclusion complexes were obtained using UV–vis and spectrofluorometric measurement. The mechanism of inclusion complexation was explored by 1H and 2D ROESY NMR spectroscopy. Binding ability of the drug molecule, Alverine citrate with the HSA and the controlled release of the drug molecule from inclusion complexes were studied at PH-7.4 by spectrofluorimetricaly. Studied phenomenon thus develops the solubility of merely soluble drug into water, consequently makes bioavailable and enriches the drug delivery system. |
abstractGer |
Solubility development of supramolecular host–guest interaction between Alverine citrate with α and β-cyclodextrins were studied throughout the article. 2:1 host to guest stoichiometry of the inclusion complexation in the solution phase were confirmed by the Job’s plot. The IR, DSC, SEM and PXRD data turn out to be supportive about the phenomenon, inclusion complexation. Association constants and thermodynamic parameters of the inclusion complexes were obtained using UV–vis and spectrofluorometric measurement. The mechanism of inclusion complexation was explored by 1H and 2D ROESY NMR spectroscopy. Binding ability of the drug molecule, Alverine citrate with the HSA and the controlled release of the drug molecule from inclusion complexes were studied at PH-7.4 by spectrofluorimetricaly. Studied phenomenon thus develops the solubility of merely soluble drug into water, consequently makes bioavailable and enriches the drug delivery system. |
abstract_unstemmed |
Solubility development of supramolecular host–guest interaction between Alverine citrate with α and β-cyclodextrins were studied throughout the article. 2:1 host to guest stoichiometry of the inclusion complexation in the solution phase were confirmed by the Job’s plot. The IR, DSC, SEM and PXRD data turn out to be supportive about the phenomenon, inclusion complexation. Association constants and thermodynamic parameters of the inclusion complexes were obtained using UV–vis and spectrofluorometric measurement. The mechanism of inclusion complexation was explored by 1H and 2D ROESY NMR spectroscopy. Binding ability of the drug molecule, Alverine citrate with the HSA and the controlled release of the drug molecule from inclusion complexes were studied at PH-7.4 by spectrofluorimetricaly. Studied phenomenon thus develops the solubility of merely soluble drug into water, consequently makes bioavailable and enriches the drug delivery system. |
collection_details |
GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_374 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2807 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 |
title_short |
Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement |
remote_bool |
true |
author2 |
Das, Koyeli Roy, Debadrita Saha, Subhadeep Roy, Mahendra Nath |
author2Str |
Das, Koyeli Roy, Debadrita Saha, Subhadeep Roy, Mahendra Nath |
ppnlink |
302469664 |
mediatype_str_mv |
c |
isOA_txt |
false |
hochschulschrift_bool |
false |
doi_str |
10.1016/j.molliq.2022.121036 |
up_date |
2024-07-06T21:45:22.297Z |
_version_ |
1803867727905947648 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV009033114</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230524151321.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230510s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.molliq.2022.121036</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV009033114</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-7322(22)02575-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.21</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Rajbanshi, Biplab</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Solubility development of supramolecular host–guest interaction between Alverine citrate with α and β-cyclodextrins were studied throughout the article. 2:1 host to guest stoichiometry of the inclusion complexation in the solution phase were confirmed by the Job’s plot. The IR, DSC, SEM and PXRD data turn out to be supportive about the phenomenon, inclusion complexation. Association constants and thermodynamic parameters of the inclusion complexes were obtained using UV–vis and spectrofluorometric measurement. The mechanism of inclusion complexation was explored by 1H and 2D ROESY NMR spectroscopy. Binding ability of the drug molecule, Alverine citrate with the HSA and the controlled release of the drug molecule from inclusion complexes were studied at PH-7.4 by spectrofluorimetricaly. Studied phenomenon thus develops the solubility of merely soluble drug into water, consequently makes bioavailable and enriches the drug delivery system.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Alverine citrate</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cyclodextrin, Human serum albumin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Controlled Drug delivery</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Inclusion Complex</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Solubility enhancement</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Das, Koyeli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roy, Debadrita</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Saha, Subhadeep</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roy, Mahendra Nath</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of molecular liquids</subfield><subfield code="d">New York, NY [u.a.] : Elsevier, 1983</subfield><subfield code="g">370</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)302469664</subfield><subfield code="w">(DE-600)1491496-7</subfield><subfield code="w">(DE-576)259483915</subfield><subfield code="x">1873-3166</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_374</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2807</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.21</subfield><subfield code="j">Lösungen</subfield><subfield code="j">Flüssigkeiten</subfield><subfield code="x">Physikalische Chemie</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">370</subfield></datafield></record></collection>
|
score |
7.399289 |